JNJ's amivantamab puts more data behind the hype

Johnson & Johnson’s amivantamab has cemented its status as the industry’s leading project for treating lung cancer driven by a rare and intractable mutation, exon 20 insertion, with highly positive data presented at the weekend’s World Lung conference.